Capricor Therapeutics, Inc.
CAPR
$8.64
-$0.42-4.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 11.13M | 13.39M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 11.13M | 13.39M |
| Cost of Revenue | 99.74M | 92.92M | 84.45M | 75.88M | 67.33M |
| Gross Profit | -99.74M | -92.92M | -84.45M | -64.75M | -53.93M |
| SG&A Expenses | 35.42M | 27.01M | 23.69M | 21.93M | 19.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 135.16M | 119.93M | 108.14M | 97.81M | 86.80M |
| Operating Income | -135.16M | -119.93M | -108.14M | -86.68M | -73.41M |
| Income Before Tax | -129.41M | -114.59M | -105.04M | -81.99M | -69.97M |
| Income Tax Expenses | 3.20K | 3.20K | 3.20K | 3.20K | 3.20K |
| Earnings from Continuing Operations | -129.42 | -114.59 | -105.04 | -81.99 | -69.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -129.42M | -114.59M | -105.04M | -81.99M | -69.98M |
| EBIT | -135.16M | -119.93M | -108.14M | -86.68M | -73.41M |
| EBITDA | -133.06M | -117.91M | -106.25M | -84.92M | -71.78M |
| EPS Basic | -2.45 | -2.31 | -2.26 | -1.80 | -1.64 |
| Normalized Basic EPS | -1.53 | -1.44 | -1.41 | -1.12 | -1.02 |
| EPS Diluted | -2.45 | -2.31 | -2.26 | -1.80 | -1.64 |
| Normalized Diluted EPS | -1.53 | -1.44 | -1.41 | -1.12 | -1.02 |
| Average Basic Shares Outstanding | 209.93M | 197.71M | 185.91M | 181.57M | 168.95M |
| Average Diluted Shares Outstanding | 209.93M | 197.71M | 185.91M | 181.57M | 168.95M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |